NextBio

Help
Description: Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.
Drug Type: Small Molecule; Approved
Pharmacology: Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.
Mechanism of Action: Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime interferes with an autolysin inhibitor.
Indication: For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes, (3) pharyngitis and tonsillitis caused by S. pyogenes, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains).
Half Life: 3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.
View Complete Description




Individual Studies
  • Broad Connectivity Map (CMAP 2.0) compound database

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    A reference collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules that enable the discovery of functional connections between drugs, genes and diseases through the transitory feature of common gene-expression changes.

    Authors: Lamb J

    Organization: Broad Institute Seven Cambridge Center C…

View All Individual Studies

Thought leaders and organizations working on research involving (-)-Cefixim.

  • Takashi Deguchi
  • Mitsuru Yasuda
  • Hartmut Derendorf
  • Shin-ichi Ito
  • Jeremy N Day
  • St. Jude Children's Research Hospital
  • Teva Pharmaceuticals USA
  • New Approaches to Neuroblastoma Therapy Consortium
  • Assistance Publique - Hôpitaux de Paris
  • Children's Hospital Medical Center, Cincinnati
  • Laboratory for the Research and Investigation of Veterinary Drugs and …
  • University of Florida
  • Prince of Wales Hospital
  • Patan Hospital
  • University of North Carolina at Chapel Hill

Community

Help for Community
  • No NextBio users were found for “(-)-Cefixim”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

  • No NextBio groups were found for “(-)-Cefixim”.
    Be the first to start a group and share your interests with others within the NextBio community.